Dapirolizumab pegol (DZP) a novel drug wc inhibits CD40L signalling. In the PHOENYCS GO trial, pts on DZP+SOC achieved
Tweet Content
Dapirolizumab pegol (DZP) a novel drug wc inhibits CD40L signalling.
In the PHOENYCS GO trial, pts on DZP+SOC achieved BICLA response at wk 48 vs. DZP+PBO
-observed efficacy in SRI4, SLEDAI2K, LLDAS, BILAG
-reduxn in steroid dose
-well tolerated
@RheumNow #ACR24 abL16 #ACRBest https://t.co/5tj2uwqeUz
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off